Literature DB >> 1827484

IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells.

D F Fiorentino1, A Zlotnik, P Vieira, T R Mosmann, M Howard, K W Moore, A O'Garra.   

Abstract

Murine IL-10 (cytokine synthesis inhibitory factor) inhibits cytokine production by Th1 cell clones when they are activated under conditions requiring the presence of APC. By preincubating APC with IL-10, we demonstrate that IL-10 acts principally on APC to inhibit IFN-gamma production by Th1 clones. Moreover, IL-10 is not active when Th1 cells are stimulated with glutaraldehyde-fixed APC, which also indicates that its action involves regulation of APC function. Furthermore, IL-10 inhibits cytokine synthesis by Th1 cells stimulated with the super-antigen Staphylococcus enterotoxin B, which does not appear to require processing. Flow microfluorimetry purified splenic or peritoneal B cells and macrophages, and B cell and macrophage cell lines can present Ag to Th1 clones. However, IL-10 acts only on sorted macrophages and the macrophage cell line to suppress IFN-gamma production by Th1 clones. IL-10 does not show this effect when B cells are used as APC. In contrast, IL-10 does not impair the ability of APC to stimulate cytokine production by Th2 cells. IL-10 does not decrease IFN-gamma-induced I-Ad levels on a macrophage cell line. Inasmuch as IL-10 also inhibits IL-2-induced IFN-gamma production by Th1 cells in an Ag-free system requiring only the presence of accessory cells, these data suggest that IL-10 may inhibit macrophage accessory cell function which is independent of TCR-class II MHC interactions.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1827484

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  490 in total

1.  Characterization of phenotype and cytokine profiles of T cell lines derived from vitreous humour in ocular inflammation in man.

Authors:  M Muhaya; V L Calder; H M Towler; G Jolly; M McLauchlan; S Lightman
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

2.  Interleukin 10 treatment for rheumatoid arthritis.

Authors:  E W St Clair
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

3.  Activation of the IL-10 gene promoter following photodynamic therapy of murine keratinocytes.

Authors:  S O Gollnick; B Y Lee; L Vaughan; B Owczarczak; B W Henderson
Journal:  Photochem Photobiol       Date:  2001-02       Impact factor: 3.421

4.  Interleukin-10 does not affect phagocytosis of particulate antigen by bone marrow-derived dendritic cells but does impair antigen presentation.

Authors:  L Faulkner; G Buchan; M Baird
Journal:  Immunology       Date:  2000-04       Impact factor: 7.397

Review 5.  Control of immune pathology by IL-10-secreting regulatory T cells.

Authors:  S Fowler; F Powrie
Journal:  Springer Semin Immunopathol       Date:  1999

6.  IL-10 secretion and sensitivity in normal human intestine and inflammatory bowel disease.

Authors:  C Gasche; S Bakos; C Dejaco; W Tillinger; S Zakeri; W Reinisch
Journal:  J Clin Immunol       Date:  2000-09       Impact factor: 8.317

Review 7.  Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance.

Authors:  Ralph Marvin Steinman; Michel C Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-02       Impact factor: 11.205

8.  Circulating immunoglobulin-bound transforming growth factor beta at a late tumour-bearing stage impairs antigen-specific responses of CD4+ T cells.

Authors:  M Harada; K Tatsugami; M Nomoto; K Nomoto
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

9.  Effects of glycyrrhizin, an active component of licorice roots, on Candida albicans infection in thermally injured mice.

Authors:  T Utsunomiya; M Kobayashi; D N Herndon; R B Pollard; F Suzuki
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

10.  Modulation of a heterologous immune response by the products of Ascaris suum.

Authors:  Jacqueline C M Paterson; Paul Garside; Malcolm W Kennedy; Catherine E Lawrence
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.